December 10, 2016 1:01 PM ET


Company Overview of Nivalis Therapeutics, Inc.

Key Executives for Nivalis Therapeutics, Inc.

NameBoard RelationshipsTitleAge
Jon Congleton 13 RelationshipsChief Executive Officer, President and Director53
R. Michael Carruthers 14 RelationshipsChief Financial Officer and Secretary58
Janice M. Troha No RelationshipsChief Operating Officer and Executive Vice President58
David M. Rodman M.D.No RelationshipsChief Medical Officer and Executive Vice President of Discovery--

Nivalis Therapeutics, Inc. Board Members*

NameBoard RelationshipsPrimary CompanyAge
Howard P. Furst M.D. 18 RelationshipsDeerfield Management Company, L.P.49
Jon Congleton 13 RelationshipsNivalis Therapeutics, Inc.53
John R. Moore 13 RelationshipsArray BioPharma Inc.52
Robert E. Conway CPA 150 RelationshipsARCA biopharma, Inc.62
Michael A. Marletta Ph.D., M.D. 20 RelationshipsThe Scripps Research Institute65
View All Board Members

Nivalis Therapeutics, Inc. Executive Committees*

Committee NameChairpersonBoard RelationshipsMembers
Audit Committee CPARobert E. Conway150 Relationships3 Executives
Compensation Committee John R. Moore13 Relationships2 Executives
Nominating Committee M.D.Howard P. Furst18 Relationships3 Executives
Corporate Governance Committee M.D.Howard P. Furst18 Relationships3 Executives
View Committee Details
*Data is at least as current as the most recent Definitive Proxy.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup


  Industry Range
Not meaningful
Total Short Term Compensation
Not meaningful
Total Value of Options$375.0K
Compensation as of Fiscal Year 2015
Nivalis Therapeutics, Inc. CEO Compensation
Industry Average


Marie Bouillez Resigns from the Board of Directors of Orgenesis Inc
December 09, 2016 10:28 PM ET
Esperion Therapeutics, Inc. Announces Transition of Roger Newton as Scientific Advisor from Executive Chairman and Chief Scientific Officer
December 09, 2016 9:30 PM ET
Shanghai Haohai Biological Technology Co., Ltd. Proposes to Appoint Tang Minjie as an Executive Director and Appoints as Chief Financial Officer
December 09, 2016 2:13 PM ET
AngioSoma, Inc. Announces Executive Changes
December 09, 2016 2:00 PM ET
Second Genome, Inc. Announces Executive Appointments
December 09, 2016 1:00 PM ET

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Nivalis Therapeutics, Inc., please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at